HIV Viral Rebound Due to a Possible Drug–Drug Interaction between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Calcium-Containing Products: Report of 2 Cases

Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) is a potent fixed-dose, once-daily regimen for HIV-1 treatment and has rare emergence of drug resistance. We report a potential drug–drug interaction in 2 female patients both receiving treatment for HIV and cerebral toxoplasmos...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang-Birken, S. Lena, El-sayed, Dena, Prichard, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6748456/
https://www.ncbi.nlm.nih.gov/pubmed/30798679
http://dx.doi.org/10.1177/2325958218821653

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6748456/
https://www.ncbi.nlm.nih.gov/pubmed/30798679
http://dx.doi.org/10.1177/2325958218821653

Ejemplares similares